Digest Network Come funziona
Network
/
Società
Za
Non verificato

Zai Lab Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

52 comunicati stampa

Guarda tutti i comunicati
06/11/2025
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
31/10/2025
Biotecnologia
Salute
Sanità
Farmaceutica
Oncologia
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Eventi
Fiere
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
24/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Web e Social Network
Telefonia e Varie
Eventi
Industria
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
15/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
13/10/2025
Sanità
Scienza
Farmaceutica
Oncologia
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Web e Social Network
Telefonia e Varie
Eventi
Industria
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
02/09/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
28/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Eventi
Web e Social Network
Zai Lab Announces Participation in Investor Conferences in September 2025
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
19/08/2025
Scienza
Attrezzature medico-sanitarie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
13/08/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Zai Lab Establishes Oncology Scientific Advisory Board
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
07/08/2025
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0